{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"487"}],"units":"Participants"}],"description":"The percentage of ATA (Also called anti-drug antibodies (ADA))-positive participants after drug administration were determined for participants exposed to atezolizumab. For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following study drug exposure, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the baseline titer result.","groups":[{"description":"Participants who did not experience disease recurrence after chemotherapy in enrollment phase received 1200 milligrams (mg) of atezolizumab intravenously (IV) every 3 weeks (Q3W) for sixteen 21-day cycles in the randomization phase.","id":"OG000","title":"Atezolizumab"}],"paramType":"NUMBER","populationDescription":"ADA evaluable population was defined as all randomized participants who received at least one dose of atezolizumab and who have at least one post-baseline ADA result.","reportingStatus":"POSTED","timeFrame":"Predose (Hour 0) on Day 1 of Cycles 2, 3, 4, 8, 16 (Cycle length = 21 days), at treatment discontinuation (TD) (up to 12 months), 120 days after last atezolizumab administration (up to 16 months)","title":"Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab","type":"SECONDARY","unitOfMeasure":"percentage of participants"}